CClinicalTrials.gg
CompletedNCT02886013Updated Sep 1, 2016

FTO rs9939609 and PPARy rs1801282 Polymorphisms in Mexican Adolescents

An observational study in Metabolic Syndrome and Insulin Resistance, sponsored by Asociación Científica Latina A.C.. Completed. Open to participants aged 14 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-01.

Sponsored by Asociación Científica Latina A.C. · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
71
Ages
14 Years to 18 Years
Sex
All
01

Study summary

Background and Aims: The presence of the FTO rs9939609 and PPARy rs1801282 polymorphisms suggests changes in energy metabolism; this variation may be responsible for the development of various diseases including obesity. The aim of this study was to identify the presence of these polymorphisms in Mexican adolescents with overweight and obesity at high risk for developing diabetes. Methods and Results: This was a descriptive cross-sectional study, where 71 healthy adolescents (average age of 16) were included. Anthropometric measurements, Body mass index, as well as the determination of glucose, insulin and HOMA index were calculated from all the patients. The FTO rs9939609 and PPARy rs1801282 polymorphisms were determined by real-time PCR.

Read the detailed description

Study Population Students without known disease, between 14 and 18 years from the "Lic. Adolfo Lopez Mateos" Preparatory school of the Autonomous University of the State of Mexico (UAEMex), were invited to participate.

Anthropometry The body mass index (BMI) was calculated as weight (kg) divided by height (m) squared with conventional stadiometer; dividing the results in normal, overweight and obesity according to the classification of the World Health Organization (WHO), specifically for adolescents by gender and age.

Laboratory 3 mL of venous blood (Vacutainer tubes) were taken in fasting. The concentration of glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were determined by enzymatic methods (Randox Laboratories Ltd, County Antrim, UK); whereas leptin and adiponectin concentrations were determined by the immunosorbent assay (ELISA) (Invitrogen MR Frederyck MD USA). A sample remained frozen at -70°C (900 series Thermo Scientific) until DNA extraction.

Genotyping DNA extraction was performed in the Magna Pure LC 2.0 Instrument (Roche, Germany) using the MagNA Pure LC DNA Isolation Kit 1 (Roche, Germany). After extraction, the DNA was quantified using a NanoPhotometer (Implen GmbH, Germany), reporting concentration (μg/ml) and purity (260/280 absorbance). Genotyping was performed by polymerase chain reaction (PCR) Life express thermal cycler (Bioer, China). The primers and conditions for each polymorphism are listed in Table 1.

The oligonucleotides were designed using the Primer Quest web tool (Integrated DNA Technologies, Inc., CA, USA) and synthesized at the Synthesis and DNA Sequencing Unit of the National Autonomous University of Mexico (UNAM) Institute of Biotechnology (Cuernavaca, Morelos, Mexico). A search was performed in BLAST to verify the correct hybridization. The final products were visualized in 2% agarose gels, stained with ethidium bromide, and visualized under an UV transilluminator (Gel Logic 212 Pro, Carestream, USA). To confirm the detection of polymorphisms sequencing was performed at the National Institute of Genomic Medicine (INMEGEN), Mexico City.

02

Conditions studied

  • Metabolic Syndrome
  • Insulin Resistance

Keywords

  • prevalence
03

In context

Metabolic Syndrome

1,963 studies on the registry are indexed under Metabolic Syndrome; 329 are open to participants now.

This study's enrollment of 71 is below the median of 200 across 458 observational studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

Asociación Científica Latina A.C. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Mexican adolescents with overweight and obesity at high risk for developing diabetes.

Inclusion criteria

  • Students without known disease, between 14 and 18 years from the "Lic. Adolfo Lopez Mateos" Preparatory school of the Autonomous University of the State of Mexico (UAEMex).

Exclusion criteria

Exclusion Criteria:

  • Those with a history of smoking, pregnancy or diagnosed with a chronic diseases.
05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
71 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Mexican adolescents

    Students without known disease, between 14 and 18 years from the "Lic. Adolfo Lopez Mateos" Preparatory school of the Autonomous University of the State of Mexico (UAEMex).

06

What researchers measure

Primary outcomes

  1. Prevalence of the FTO rs9939609 and PPARy rs1801282 polymorphisms.

    The aim of this study was to identify the presence of these polymorphisms in Mexican adolescents with overweight and obesity at high risk for developing diabetes.

    Time frame: up to 24 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02886013
Lead sponsor
Asociación Científica Latina A.C.
Responsible party
Dr. Hugo Mendieta Zerón (Director, Asociación Científica Latina A.C.) — Principal investigator
First posted
Sep 1, 2016
Start date
Jan 2013
Primary completion
Aug 2014
Completion
Aug 2015
Last update
Sep 1, 2016

Study contacts

María del Socorro Camarillo Romero, PhD.
study chair · Autonomous University of the State of Mexico

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion